Vol 7, No 2 (2022)
Original article
Published online: 2022-04-19

open access

Page views 4289
Article views/downloads 390
Get Citation

Connect on Social Media

Connect on Social Media

Two different approaches to assess adherence to medication in Polish cohort of the EUROASPIRE V registry

Aldona Kubica1, Piotr Michalski1, Michał Kasprzak2, Łukasz Pietrzykowski1, Tomasz Fabiszak2, Joanna Siódmiak3, Krzysztof Buczkowski4, Piotr Jankowski56
Medical Research Journal 2022;7(2):108-113.


Introduction: The implementation of guidelines on cardiovascular disease (CVD) prevention in patients at
high risk of developing CVD was assessed in the EUROASPIRE V registry.
Aim of the study: This study was designed to compare a simple self-reported quantitative assessment of
adherence to medication using the Medication Adherence Questionnaire (MAQ) with a qualitative evaluation
based on the Adherence in Chronic Disease Scale (ACDS) in the Polish cohort of the EUROSPIRE V registry.
Material and methods: The study was performed in 200 patients (133 women and 67 men) with an average
age of 51.49 (13.63) years and a history of hypertension, hypercholesterolemia or diabetes, but without prior
cardiovascular events. Pharmacological treatment was applied in 127 patients (63.5%) with hypertension,
90 (45%) with hypercholesterolemia, and 31 (15.5%) with diabetes.
Results: According to the MAQ, high adherence to medication (100% or 90%) was declared by 67.7%
of patients, while medium (75% or 50%) and low adherence (< 50% or 0%) by 9.7% and 22.6%, respectively.
The adherence assessed with the ACDS, was high in 38.7%, medium in 44.8%, and low in 16.5%
of patients. A remarkable inconsistency between ACDS and MAQ responses was found. The MAQ and
the ACDS rendered consistent results in 44.8% of patients (111 out of 148), while in the remaining 55.2%
(137 out of 248) of patients the results were discordant.
Conclusions: The assessment of medication adherence based on patient declarations used in the EUROASPIRE
V registry is likely to overestimate the frequency of high adherence.

Article available in PDF format

View PDF Download PDF file


  1. Kotseva K, De Backer G, De Bacquer D, et al. EUROASPIRE Investigators*. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol. 2019; 26(8): 824–835.
  2. Kubica A, Grześk G, Sinkiewicz W, et al. Compliance, concordance, adherence w przewlekłej terapii. Folia Cardiologica Excerpta. 2010; 5(2): 54–57.
  3. Kubica A, Kasprzak M, Obońska K, et al. Discrepancies in assessment of adherence to antiplatelet treatment after myocardial infarction. Pharmacology. 2015; 95(1-2): 50–58.
  4. Pietrzykowski Ł, Kasprzak M, Michalski P, et al. The influence of patient expectations on adherence to treatment regimen after myocardial infarction. Patient Educ Couns. 2022; 105(2): 426–431.
  5. Kubica A, Kasprzak M, Siller-Matula J, et al. Time-related changes in determinants of antiplatelet effect of clopidogrel in patients after myocardial infarction. Eur J Pharmacol. 2014; 742: 47–54.
  6. Buszko K, Obońska K, Michalski P, et al. The Adherence Scale in Chronic Diseases (ASCD). The power of knowledge: the key to successful patient — health care provider cooperation. Medical Research Journal. 2016; 1(1): 37–42.
  7. Kubica A, Kosobucka A, Michalski P, et al. The Adherence in Chronic Diseases Scale — a new tool to monitor implementation of a treatment plan. Folia Cardiol. 2017; 12(1): 19–26.
  8. Kubica A, Kosobucka A, Fabiszak T, et al. Assessment of adherence to medication in patients after myocardial infarction treated with percutaneous coronary intervention. Is there a place for newself-reported questionnaires? Curr Med Res Opin. 2019; 35(2): 341–349.
  9. Kosobucka A, Michalski P, Pietrzykowski Ł, et al. Adherence to treatment assessed with the Adherence in Chronic Diseases Scale in patients after myocardial infarction. Patient Prefer Adherence. 2018; 12: 333–340.
  10. Michalski P, Kasprzak M, Pietrzykowski Ł, et al. Ambulatory assessment of medication adherence in high cardiovascular-risk patients. The Polish population of the EUROASPIRE V survey. Medical Research Journal. 2021; 6(4): 316–321.
  11. Kotseva K, De Backer G, De Bacquer D, et al. EUROASPIRE V Investigators. Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries. Eur J Prev Cardiol. 2021; 28(4): 370–379.
  12. De Bacquer D, Astin F, Kotseva K, et al. EUROASPIRE IV and V surveys of the European Observational Research Programme of the European Society of Cardiology. Poor adherence to lifestyle recommendations in patients with coronary heart disease: results from the EUROASPIRE surveys. Eur J Prev Cardiol. 2022; 29(2): 383–395.
  13. Laskowska E, Michalski P, Pietrzykowski Ł, et al. Implementation of therapeutic recommendations in high cardiovascular-risk patients. The Polish population of EUROASPIRE V survey. Medical Research Journal. 2021; 6(3): 230–236.
  14. Lam WY, Fresco P. Medication adherence measures: an overview. Biomed Res Int. 2015; 2015: 217047.
  15. Garber MC, Nau DP, Erickson SR, et al. The concordance of self-report with other measures of medication adherence: a summary of the literature. Med Care. 2004; 42(7): 649–652.
  16. Cook CL, Wade WE, Martin BC, et al. Concordance among three self-reported measures of medication adherence and pharmacy refill records. J Am Pharm Assoc (2003). 2005; 45(2): 151–159.
  17. Vik SA, Maxwell CJ, Hogan DB. Measurement, correlates, and health outcomes of medication adherence among seniors. Ann Pharmacother. 2004; 38(2): 303–312.
  18. Wang PS, Benner JS, Glynn RJ, et al. How well do patients report noncompliance with antihypertensive medications?: a comparison of self-report versus filled prescriptions. Pharmacoepidemiol Drug Saf. 2004; 13(1): 11–19.
  19. Frost MH, Reeve BB, Liepa AM, et al. Mayo/FDA Patient-Reported Outcomes Consensus Meeting Group. What is sufficient evidence for the reliability and validity of patient-reported outcome measures? Value Health. 2007; 10(Suppl 2): S94–S104.
  20. Kubica A, Kosobucka A, Michalski P, et al. Self-reported questionnaires for assessment adherence to treatment in patients with cardiovascular diseases. Medical Research Journal. 2018; 2(4): 115–122.
  21. Kubica A, Obońska K, Fabiszak T, et al. Adherence to antiplatelet treatment with P2Y12 receptor inhibitors. Is there anything we can do to improve it? A systematic review of randomized trials. Curr Med Res Opin. 2016; 32(8): 1441–1451.
  22. Kubica A, Obońska K, Kasprzak M, et al. Prediction of high risk of non-adherence to antiplatelet treatment. Kardiol Pol. 2016; 74(1): 61–67.
  23. Kubica A, Adamski P, Bączkowska A, et al. The rationale for Multilevel Educational and Motivational Intervention in Patients after Myocardial Infarction (MEDMOTION) project is to support multicentre randomized clinical trial Evaluating Safety and Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndrome (ELECTRA – SIRIO 2). Medical Research Journal. 2020; 5(4): 244–249.